12:00 AM
 | 
May 26, 2014
 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones
Regulatory milestones

AB Science S.A. (Euronext:AB) was up €0.29 to €11.32 on Friday after EMA's CHMP reiterated its recommendation against conditional approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic cancer in combination with gemcitabine. The company said it plans to resubmit the MAA and seek full approval with data from a planned Phase III confirmatory trial; data are expected in 2H17.

AB Science was off €0.15 last week.

Active Biotech AB (SSE:ACTI) was off SEK0.20 to SEK35.50 on Friday after EMA's CHMP reiterated a recommendation against approval of Nerventra laquinimod to treat relapsing-remitting multiple sclerosis (RRMS). Partner Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), which was up $1.11 to $51.77 on Friday, said it plans to continue the Phase III CONCERTO trial of Nerventra in RRMS.

Last week, Teva gained $1.96. Active Biotech gained SEK0.10.

Biogen Idec Inc. (NASDAQ:BIIB) gained $0.02 to $299.71 Friday after EMA's CHMP backed approval of Plegridy peginterferon beta-1a (BIIB017) to treat relapsing-remitting multiple sclerosis (RRMS). A BLA is under FDA review for relapsing forms of MS, with a decision expected next half. Last week, Biogen Idec was up $8.39.

Durata Therapeutics Inc. (NASDAQ:DRTX) gained $0.88 to $16.89 on Friday after FDA approved Dalvance dalbavancin to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The agency said Dalvance is the first drug with Qualified Infectious Disease Product (QIDP) designation to receive FDA approval, qualifying Dalvance for an additional five years of market exclusivity.

Last week, Durata gained $0.96

Endocyte Inc. (NASDAQ:ECYT) gained a penny to $6.53 last week after partner Merck & Co. Inc. (NYSE:MRK) withdrew an MAA from EMA seeking conditional approval of Vynfinit vintafolide to treat ovarian cancer. The partners made the decision based on interim data from the Phase III PROCEED trial, which was suspended this month after...

Read the full 1591 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >